Pli­ant claims ear­ly win for in­te­grin in­hibitor in chal­leng­ing IPF space — shares soar

With a num­ber of com­pa­nies — in­clud­ing Bris­tol My­ers Squibb — look­ing to drug TGF-β for a spec­trum of can­cers and fi­brot­ic dis­eases, Pli­ant Ther­a­peu­tics is tout­ing ear­ly da­ta for its TGF-β in­hibitor for id­io­path­ic pul­monary fi­bro­sis (IPF).

Pli­ant’s Phase II tri­al for its lead can­di­date met the pri­ma­ry end­point in tol­er­a­bil­i­ty, as 65 of 67 pa­tients com­plet­ed the 12-week treat­ment course, the Bay Area biotech an­nounced yes­ter­day.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER